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Abstract
Missense mutations in TP53 are common in human breast cancer, have been associated with worse 
prognosis, and may predict therapy effect. TP53 missense mutations are associated with aberrant 
accumulation of p53 protein in tumor cell nuclei. Previous studies have used relatively arbitrary 
cutoffs to characterize breast tumors as positive for p53 staining by immunohistochemical assays. 
This study aimed to objectively determine optimal thresholds for p53 positivity by manual and 
automated scoring methods utilizing whole tissue sections from the Carolina Breast Cancer Study. 
P53 immunostained slides were available for 564 breast tumors previously assayed for TP53 
mutations. Average nuclear p53 staining intensity was manually scored as negative, borderline, 
weak, moderate, or strong and percentage of positive tumor cells was estimated. Automated p53 
signal intensity was measured using the Aperio nuclear v9 algorithm combined with the Genie® 
histology pattern recognition tool and tuned to achieve optimal nuclear segmentation. ROC curve 
analysis was performed to determine optimal cutoffs for average staining intensity and percent 
cells positive to distinguish between tumors with and without a missense mutation. ROC curve 
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analysis demonstrated a threshold of moderate average nuclear staining intensity as a good 
surrogate for TP53 missense mutations in both manual (AUC=0.87) and automated (AUC=0.84) 
scoring systems. Both manual and automated immunohistochemical scoring methods predicted 
missense mutations in breast carcinomas with high accuracy. Validation of the automated intensity 
scoring threshold suggests a role for such algorithms in detecting TP53 missense mutations in high 
throughput studies.
Keywords
TP53; missense mutation; breast cancer; immunohistochemistry; image analysis; automated 
scoring; algorithm
 Introduction
The tumor suppressor gene TP53 is one of the most commonly mutated genes in human 
neoplasia in general and in breast cancer in particular. Overall, 23-30% of human breast 
carcinomas harbor TP53 mutations [1-4]. These mutations are readily detectable by various 
DNA sequencing techniques; however, those assays are rarely performed in routine clinical 
practice. Approximately 70-75% of TP53 mutations are missense mutations and lead to 
accumulation of abnormal p53 protein in the nuclei of tumor cells [5,6]. While levels of 
wild- type p53 are typically very low, accumulation of mutant p53 can be detected by 
immunohistochemistry (IHC), a technique that is extensively used in pathology laboratories. 
Increased levels of p53 as detected by IHC have been widely used as a surrogate for 
detection of an underlying TP53 mutation, although non-missense mutations are typically 
not detected by this method (false negatives) [7,8] and accumulation of wild-type p53 under 
certain circumstances can lead to false positive results.
P53 is thought to play an important role in the etiology of breast carcinomas owing to its 
importance in regulating the cell cycle and apoptosis [9,10]; and p53 expression has been 
studied as a biomarker in human mammary neoplasia where it has been found to be a 
prognostic factor and to predict response to radiation, endocrine and chemotherapy [11,12]. 
However, the literature on the clinical significance of p53 in breast cancer is not consistent. 
This may be due in part to the fact that p53 over expression has been variably defined, and 
the great majority of studies have used arbitrary cutoffs. The primary goal of our study was 
to determine a rational threshold for IHC assessment of p53 protein overexpression to act as 
a surrogate for a TP53 missense mutation.
A second aim of our study was to establish a cutoff value that would distinguish tumors with 
and without TP53 missense mutations utilizing automated image analysis of p53 
immunostained slides. Immunohistochemical stains of smaller series of tumors lend 
themselves to manual scoring. However, an increasing number of clinical and especially 
epidemiological studies include very large numbers of cases, and many of them utilize tissue 
microarrays (TMAs). Consequently these studies involve thousands of tissue samples that 
need to be scored, often for a long list of biomarkers. Image analysis is a helpful tool in 
scoring large numbers of immunohistochemical stains. Rational thresholds for manual and 
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automated scoring of p53 immunostains should prove useful for researchers studying the 
role of p53 in breast cancer and other epithelial malignancies.
 Materials and Methods
 Study Population
The Carolina Breast Cancer Study (CBCS) is a population-based, case-control study of 
genetic and environmental risk factors for breast cancer among African American and 
Caucasian women residing in North Carolina [13]. Eligible cases were women aged 20-74 
years with a first primary diagnosis of invasive breast cancer between 1993 and 1996 (Phase 
1 of the CBCS), and were identified by the North Carolina Central Cancer Registry via a 
rapid case ascertainment protocol [14]. The distributions of pathological features and 
biomarkers in our study population have been previously described [15]. African American 
cases and women diagnosed before age 50 were oversampled to ensure that they comprised 
approximately half of recruited case participants [14]. The CBCS conducted two recruitment 
phases subsequent to Phase 1, and TP53 mutational data for those cases was not collected. 
Detailed CBCS study methods have been previously described [13]. A total of 861 breast 
cancer cases were eligible for and consented to participate in Phase 1 of the CBCS [14]. 
Clinical data and information on tumor characteristics were obtained from medical records 
or direct pathological review of tumor tissue [14]. All study procedures were approved by 
the University of North Carolina School of Medicine Institutional Review Board.
 TP53 Mutation Screening
A screening algorithm incorporating single-strand conformational polymorphism (SSCP) 
analysis and manual DNA sequencing was employed to evaluate mutations in exons 4-8 of 
the TP53 gene [16,17]. Briefly, PCR amplification was carried out for exons 5-8, while exon 
4 was amplified as two overlapping segments. Detailed mutation screening has been 
previously described [14].
 Tumor Tissue Preparation and Histopathological Evaluation
Tumor tissue from formalin-fixed, paraffin-embedded tumor blocks was obtained for 798 of 
the 861 breast cancer cases (93%) and sectioned as previously described [18]. Tissue 
sections underwent standardized histopathological review by the study pathologist (JG). The 
invasive components of the tumors were identified by the study pathologist and selectively 
dissected for molecular analyses by a proteinase K extraction method as previously 
described [16,17]. We analyzed TP53 mutational status for 564 (71%) of the 798 cases for 
whom tissue was obtained. Of the 234 tumors not evaluated, 210 were determined by 
histopathological review to have insufficient tumor volume for molecular analysis and 24 
tumors could not be assessed because of poor DNA quality. Four- micron paraffin sections 
were stained for p53 protein as previously described [19]. Briefly, sections underwent heat 
induced epitope retrieval in sub-boiling citrate buffer (pH 6.0) for 10 minutes. Mouse 
monoclonal p53 antibody clone DO7 (Dako, Glostrup, Denmark) was applied at a 1:100 
dilution and incubated in a humidity chamber for 1 hour. The detection reaction utilized the 
Vector Labs Elite ABC Kit with Innovex Biosciences 3,3’-diaminobenzidine as chromogen 
and hematoxylin as counterstain. A board certified pathologist (JG) performed manual 
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histopathological review of these tissue slides, recording percentage of positive cells and 
average nuclear staining intensity on a five-category scale: negative, borderline, weak, 
moderate, and strong. The reviewing pathologist assessed p53 staining across the entire 
tumor section and was blinded to other pathological and biomarker data, as well as TP53 
mutational status. Additionally, a modified histoscore (H-score) [20] was calculated as the 
product of the manually scored average staining intensity score (0 for no staining, 0.5 for 
borderline, 1 for weak, 2 for moderate, 3 for strong) and manually estimated percentage of 
positive tumor cells (range 0-300). The borderline category was added because some tumors 
contained nuclei that were not completely negative but were very faintly stained, 
significantly less than weakly stained nuclei.
 Aperio Automated Analysis
P53 stained slides were digitally imaged at 20× magnification using the Aperio ScanScope 
XT (Aperio Technologies, Vista, CA). Digital images were stored and analyzed within the 
Aperio Spectrum Database. P53 signal intensity was measured using the Aperio nuclear v9 
algorithm (cell quantification) combined with the Genie® Histology Pattern Recognition 
tool. Genie® was used to exclude from the analysis artifacts related to the tissue processing 
(ink) and the sectioning and staining protocol (folds, debris). Algorithm parameters, 
including nuclear compactness, curvature and intensity thresholds, maximum and minimum 
nuclear size and hematoxylin optical density were tuned to achieve optimal nuclear 
segmentation. The Aperio v9 algorithm uses a 3-point scale to score average staining 
intensity, with a 1+ score indicating relative lack of staining intensity (corresponding to 
combined manual scores of negative, borderline, and weak), a 2+ score indicating relatively 
moderate staining intensity and a 3+ score corresponding to relatively strong staining 
intensity.
 Statistical Analysis
Receiver operating characteristic curve (ROC) analysis was performed to assess the accuracy 
and optimal threshold of p53 staining (average intensity, percent positive tumor cells, 
modified H-score) to predict the presence of a missense mutation in TP53. TP53 mutational 
status was dichotomized, with a missense mutation representing the index category and all 
other mutational dispositions (no mutation, silent mutation, non-missense mutation) coded 
as referent. Unconditional logistic regression was also performed to evaluate the association 
between missense mutations in TP53 and average p53 protein IHC nuclear staining intensity. 
All statistical analyses were performed using SAS v9.3 software (SAS Institute, Cary, NC).
 Results
Figure 1 illustrates the manually scored staining intensity categories. Figure 2 shows the 
distribution of p53 staining across the cohort of 564 breast carcinomas. Seventy-six tumors 
(13.5%) were completely devoid of nuclear staining, 336 (59.6%) showed borderline or 
weak nuclear staining, and 152 (27.0%) showed moderate or strong nuclear staining (Panel 
2a). Among the 152 tumors with moderate or strong nuclear staining, 104 (68.4%) had 
>70% cells showing positivity for p53 (Panel 2b). Across the entire cohort, 374 tumors 
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(66.3%) showed reactivity in less than 30% of tumor cells while 118 tumors (20.9%) had 
staining in over 70% of tumor cells (Panel 2c).
Examination of agreement between manual (3-category with combined negative, borderline, 
and weak serving as referent category) and automated systems for scoring average nuclear 
p53 staining intensity indicated good correlation (Spearman’s ρ=0.80). Using 3-category 
coding, agreement was 81.6% (Table 1). Dichotomizing the stains into negative (manual 
scores of negative, borderline, and weak combined; automated scores of 1) versus positive 
(manual scores of moderate and strong combined; automated scores of 2 and 3 combined) 
increased concordance to 91.5% (Table 1). ROC curve analysis revealed that a 3-category 
manual scoring system of average nuclear staining intensity (Figure 3b; AUC=0.87) was 
comparable to the previously used 5-category scale (Figure 3a; AUC=0.90). We noted that 
the AUC was slightly augmented by combining percentage cells positive and average 
nuclear staining intensity into a modified H-score with an optimal cut point of 60 (Figure 3c; 
AUC=0.92). The ROC curve for the automated 3-category scoring algorithm (Figure 3d; 
AUC=0.84) showed similar results to the corresponding 3-category manual scoring system. 
Both manual and automated scoring systems had an optimal threshold of at least moderate 
average nuclear staining.
Manual and automated scores of average p53 nuclear staining intensity showed similar 
predictive capacity for TP53 missense mutations. Manual scoring correctly classified 96 of 
113 missense mutations (sensitivity=0.85) and 372 of 422 tumors without such mutations 
(specificity=0.88). The automated scoring system correctly classified 83 of 113 missense 
mutations (sensitivity=0.73) and 393 of 422 tumors without such mutations 
(specificity=0.93) (Table 2).
When scored manually, an average nuclear staining intensity of at least moderate, ≥ 50% 
positive tumor cells, and a modified H-score of at least 60 had comparable sensitivities and 
specificities with regard to prediction of TP53 missense mutations; the automated scoring 
algorithm performed similarly to the manual system, although a lower sensitivity was noted 
while specificity was slightly higher (Table 3). Odds ratios (ORs) and 95% confidence 
intervals (CIs) estimating the association between manually scored average p53 nuclear 
staining intensity and presence of a missense mutation suggested robust prediction of a 
missense mutation when moderate to strong average nuclear staining intensity was observed 
(OR= 42.01; 95% CI: 23.19, 76.10) (Table 3). These findings were recapitulated using the 
Aperio v9 automated algorithm (OR=37.49; 95% CI: 21.36, 65.81) (Table 3).
Finally, using a scoring threshold of at least moderate average nuclear staining, we examined 
the automated scoring system’s capacity to detect differential frequencies of TP53 missense 
mutations in 1) pre- versus post-menopausal breast carcinomas and 2) major breast cancer 
subtypes. As summarized in Table 4, moderate or strong average nuclear p53 staining 
intensity was more common in HER2-positive and premenopausal breast carcinomas, 
consistent with the TP53 mutational analysis.
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 Discussion
It is well established that TP53 plays an important role in the pathogenesis of human breast 
cancer, owing to its importance in regulating both the cell cycle and apoptosis [9,10]. Most 
TP53 mutations are associated with decreased degradation of p53, leading to accumulation 
of the protein in tumor cells that is detectable as increased nuclear staining by IHC [5]. 
Mutant p53 is known to demonstrate gain-of-function oncogenic activity by binding and 
inactivating other regulatory proteins, such as p63 and p73 [21], and ovarian cancer patients 
carrying such gain-of-function missense mutations in TP53 showed greater resistance to 
platinum agents when compared to those without gain-of-function missense mutations [22]. 
Thus, identifying cancer patients carrying missense mutations in TP53 may be relevant to 
the selection of appropriate adjuvant therapy. Furthermore, TP53 mutations have been 
reported more often in basal-like and HER2+/ER- breast cancer subtypes compared to 
luminal breast cancers [23], and recent exome sequencing studies in TCGA have 
demonstrated that TP53 mutation type may differ by breast cancer molecular subtype [24]. 
Consequently, the utility of IHC to identify TP53 missense mutations in breast cancer may 
depend upon the tumor characteristics of a given population.
While mutational TP53 analysis is not routinely performed on human cancer specimens, 
IHC is a commonly used technique in pathology laboratories. IHC is frequently employed as 
a surrogate for TP53 mutational analysis, but suffers interpretability issues related to both 
false positive and false negative staining [25,26]. Despite these limitations, over expression 
of p53 has been shown to be a negative prognostic indicator in breast cancer [27,28] and has 
been associated with poor response to adjuvant endocrine [29,30], radiation [12], and 
chemotherapy [12]; additionally, p53 over expression has been associated with poor 
response to neoadjuvant chemotherapy [8,31,32]. However, rationally defined cut points for 
abnormally high p53 expression have been lacking, and few studies have utilized TP53 
mutational data as a gold standard to calibrate p53 IHC scoring thresholds. The absence of 
objective cut points may partially explain why published data on p53 as a prognostic or 
predictive factor for human breast cancer have not been consistent [33,34].
Previous studies defined p53 over expression as: a certain minimum percentage of tumor 
cells demonstrating IHC staining, a certain minimum IHC staining intensity, or a 
combination of both. We tested all three models and found that cut points of 50% cells 
positive, moderate average nuclear staining intensity and a modified H-score of 60 all had 
comparable performance characteristics, as may be inferred from Figure 3 and Table 3. 
These results are consistent with previous studies using thresholds of 50% positive cells 
[35-37] or moderate staining intensity [38] as cutoffs for p53 over expression. Moreover, we 
found that IHC is a good surrogate for identifying TP53 missense mutations in exons 4-8, 
with accuracy approaching 90%. We did not examine mutations outside of exons 4-8, and it 
is possible that exclusion of potential missense mutations in these regions may have biased 
our results. However, previous reports have indicated a majority of missense mutations in 
TP53 are found within exons 4-8, with the promoter region, exons 1-3 and 9 containing few 
to none [39].
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Our observation that a moderate or strong staining intensity is as informative as the 
percentage of positive cells or a certain H-score suggests great utility from an automated 
scoring perspective. Automated scoring algorithms have proved quite useful in measuring 
staining intensities, but have performed suboptimally in differentiating relevant (malignant) 
and irrelevant (benign) cells. Thus, scoring algorithms that include a percentage threshold 
typically do not lend themselves to automated analysis of human tumor samples stained for 
p53 or other immunohistochemical markers. Many contemporary clinical and 
epidemiological studies include over 1,000 samples, making manual scoring of IHC stains 
an onerous and lengthy task; utilizing automated algorithms to perform these high 
throughput tasks could improve efficiency and reduce variability. While pathologists often 
use a negative/weak/moderate/strong scale for manual scoring of immunohistochemical 
stains, these schemes inherently include an element of subjectivity; however, a strength of 
our study was that all cases were centrally scored by a single pathologist. A significant 
advantage of automated scoring algorithms is their ability to improve inter-observer 
concordance in the quantitation of IHC stains [40].
While sequencing approaches are becoming more cost-effective, they still rely on 
availability of sufficient DNA and are more costly than IHC assays. The efficiency of IHC in 
large epidemiologic studies ensures this approach will continue to be of value, despite 
potential misclassification rates. Better characterization of this misclassification will 
improve interpretation of IHC surrogates as predictors for TP53 mutational status. As may 
be inferred from Table 4, using an automated threshold of at least moderate average nuclear 
staining intensity demonstrated the higher prevalence of p53 over expression in HER2+/ER- 
and premenopausal breast carcinomas as reliably, if not better than, the DNA-based 
sequencing approach that shows higher frequencies of TP53 missense mutations in the same 
sub-groups.
To the best of our knowledge, our study is the first to calibrate and validate the Aperio p53 
automated scoring algorithm in human breast carcinomas. The data we present here provide 
compelling evidence that a threshold of at least moderate average nuclear staining intensity 
is a good surrogate for detection of TP53 missense mutations, and this threshold translates 
well when applied to automated p53 staining intensity scoring algorithms.
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AUC Area under the curve
CBCS Carolina Breast Cancer Study
CI Confidence interval
IHC Immunohistochemistry/immunohistochemical
H-score Histoscore
JG Joseph Geradts
OR Odds ratio
ROC Receiver operating characteristic
SSCP Single-strand conformational polymorphism
TMA Tissue microarray(s)
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Figure 1. Examples of manually scored p53 staining intensity categories
a. No staining (0)
b. Borderline staining (0.5)
c. Weak staining (1)
d. Moderate staining (2)
e. Strong staining (3)
Taylor et al. Page 11
Appl Immunohistochem Mol Morphol. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Distribution of manually scored p53 staining in breast carcinomas
a. Distribution of average nuclear staining intensity (5-category; 564 cases)
b. Distribution of percentage positive tumor cells by decile (moderate and strong 
average nuclear staining only; 152 cases)
c. Distribution of percentage positive tumor cells by decile (all tumors; 564 cases)
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Figure 3. Receiver operating characteristic (ROC) curves for the association between TP53 
mutational status and p53 protein staining intensity
a. ROC curve plot of 5-category manually scored IHC staining intensity 
predicting missense mutations in TP53 versus all other mutations or wild type 
(AUC=0.90). Labels contain staining intensity value/sensitivity/specificity. 
Staining intensity values are coded as: 0=negative, 0.5=borderline, 1=weak, 
2=moderate, 3=strong.
b. ROC curve plot of 3-category manually scored IHC staining intensity 
predicting missense mutations in TP53 versus all other mutations or wild type 
(AUC=0.87). Labels contain staining intensity value/sensitivity/specificity. 
Staining intensity values are coded as: 0=negative/borderline/weak, 
1=moderate, 2=strong.
c. ROC curve plot of modified H-score predicting a missense mutation in TP53 
versus all other mutations or wild type (AUC=0.92). Labels contain modified 
H-score value/sensitivity/specificity.
d. ROC curve plot of IHC staining intensity predicting a missense mutation in 
TP53 versus all other mutations or wild type using 3-category automated 
scoring (AUC=0.84). Labels contain staining intensity value/sensitivity/
specificity. Staining intensity values are coded as: 0=negative/low, 1=moderate, 
2=strong.
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Table 1
Manual versus automated immunohistochemical scores for average nuclear p53 staining intensity
Manual Score
Automated Score
1 2 3 Total
Negative, Borderline, Weak 405 (71.8%) 4 (0.71%) 3 (0.53%) 412 (73.1%)
Moderate 41 (7.3%) 33 (5.9%) 54 (9.6%) 128 (22.7%)
Strong 0 2 (0.35%) 22 (3.9%) 24 (4.3%)
Total 446 (79.1%) 39 (6.9%) 79 (14.0%) 564 (100%)
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Table 2
Manual versus automated average immunohistochemical p53 protein staining intensity scores as predictors of 
TP53 missense mutations
Missense Mutation
AccuracyPresent Absent
Manual Score1
+ 96 50
0.87
- 17 372
Automated Score2
+ 83 29
0.89
- 30 393
1
Positivity is defined as moderate or strong average nuclear staining intensity based on a 5-category scale (Negative-Strong)
2
Positivity is defined as 2 or 3 average staining intensity based on Aperio 3-category scale
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Table 3
Performance characteristics of manual and automated immunohistochemical scoring thresholds for the 
prediction of TP53 missense mutations
Manual Scoring AUC1 Sensitivity Specificity OR (95% CI)2
Intensity ≥ moderate (5-category)3 0.90 0.85 0.88 42.01 (23.19, 76.10)
Intensity ≥ moderate (3-category)4 0.87 0.85 0.88 42.01 (23.19, 76.10)
≥ 50% cells positive 0.93 0.90 0.88 46.23 (24.03, 88.93)
Modified H-score ≥ 605 0.92 0.89 0.88 61.23 (31.45, 119.20)
Automated Scoring
Intensity ≥ 2 (3-category) 0.84 0.73 0.93 37.49 (21.36, 65.81)
1Area under the receiver operating characteristic curve
2Odds ratios and 95% confidence intervals for the association between scoring parameter and a missense mutation in TP53
3Odds ratio calculated based on referent category combining negative, borderline, and weak staining intensities
4All calculations based on a referent category combining negative, borderline, and weak staining intensities
5A combination score incorporating percentage cells positive and average nuclear staining intensity
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Table 4
Odds ratios (OR) and 95% confidence intervals (CI) for the associations between TP53 mutational status & 
automated nuclear p53 staining intensity and molecular breast cancer subtype & menopausal status in the 
Carolina Breast Cancer Study
TP53 Missense Mutation1 Automated Average p53 Staining Intensity2
Molecular Breast Cancer Subtype
Luminal A 1.00 1.00
Luminal B 1.12 (0.56, 2.23) 1.46 (0.74, 2.89)
HER2+/ER- 1.65 (0.64, 4.24) 2.73 (1.12, 6.64)
Basal-like 1.26 (0.65, 2.44) 1.33 (0.68, 2.63)
Unclassified 0.81 (0.26, 2.50) 1.63 (0.60, 4.38)
Menopausal Status3
Postmenopausal 1.00 1.00
Premenopausal 1.85 (1.19, 2.86) 1.78 (1.17, 2.72)
1A missense mutation was coded as the index category with all other dispositions (no mutation, silent mutation, nonsense mutation) coded as the 
referent category
2Automated staining intensity of ≥ 2 was coded as the index category with staining intensity of 1 coded as the referent category
3
For women under the age of 50, menopausal status was assigned to those who had undergone natural menopause, bilateral oopherectomy, or 
irradiation to the ovaries; in women aged 50 and over, menopausal status was assigned on the basis of cessation of menstruation
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